{
    "nctId": "NCT00020722",
    "briefTitle": "Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer",
    "officialTitle": "Treatment of Stage IV Breast Cancer With Activated T Cells After Peripheral Blood Stem Cell Transplant (Pilot Phase II)",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 7,
    "primaryOutcomeMeasure": "Disease-free Survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Women with histologically documented metastatic carcinoma of the breast\n\n  * Bilateral disease allowed\n  * Concurrent intraductal or lobular carcinoma in situ allowed\n* Measurable or evaluable recurrent metastatic disease (stage IV) documented by radiograph, CT scan, nuclear medicine scan, or physical exam\n\n  * Biopsy of recurrent site(s) recommended but not required\n  * Nonmeasurable disease allowed if tumor or metastatic disease has been previously removed or successfully treated\n* 0 to 3+ HER2 amplification, as determined by FISH\n* No clinical evidence of active brain metastases\n\n  * Patients with treated brain metastases (i.e., those who have received definitive radiation, chemotherapy, and/or underwent surgery) and are stable are eligible\n* Hormone receptor status:\n\n  * Estrogen or progesterone receptor positive or negative\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Karnofsky performance status 70-100% OR ECOG performance status 0-2\n* Life expectancy at least 3 months\n* Granulocyte count at least 1,500/mm\\^3\n* Platelet count at least 50,000/mm\\^3\n* Hemoglobin greater than 8 g/dL\n* Bilirubin less than 1.5 times normal\n* AST, ALT, and alkaline phosphatase \\< 5 times upper normal\n* Creatinine less than 1.8 mg/dL\n* Creatinine clearance at least 60 mL/min\n* BUN less than 1.5 times normal\n* No myocardial infarction (MI) within the past year\n* No history of MI (\\> 1 year ago) with current coronary symptoms requiring medication\n* No current history of angina/coronary symptoms requiring medication\n* No clinical evidence of congestive heart failure requiring medical management\n* No significant congestive heart failure\n* No other uncontrolled or significant cardiovascular disease\n* Ejection fraction at least 45% at rest by MUGA\n* Systolic BP \\< 130 mm Hg and diastolic BP \\< 80 mm Hg\n\n  * BP must be controlled to meet the standard by anti-hypertensive medications for at least 7 days prior to the first infusion\n* PFT-FEV_1 at least 50% predicted\n* DLCO2 at least 50% predicted\n* FVC at least 50% predicted\n* No other malignancy within the past 3 years\n* No other serious medical or psychiatric illness that would preclude study participation\n* HIV negative\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Prior chemotherapy regimens allowed, including prior treatment on protocol WSU-2006-130\n* Prior vaccine therapy on protocol WSU-2006-130 allowed\n* More than 4 weeks to leukapheresis since prior hormonal therapy\n* No radiation to the axial skeleton within 4 weeks of leukapheresis\n* No concurrent hormonal therapy for breast cancer\n\n  * Hormones administered for non-disease-related condition (e.g. insulin for diabetes) allowed\n* Concurrent steroids for adrenal failure, septic shock, or pulmonary toxicity allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}